Putra Nilai, 4th February, 2016 : Inno Bio Ventures (IBV) today signed a memorandum of understanding (MoU) with Clinical Research Malaysia (CRM). The signing ceremony marked not only the collaboration between these two main players but also the Drug of Neglected Disease group. Most importantly the project also has a strong support from the Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Health (MOH). The MoU covers the clinical study of three drugs for the treatment of Hepatits C.
Through the collaboration, CRM will undertake the clinical research portion whereas IBV will be leading the discussion for commercialisation initiatives. The project objective is to assess the effectiveness of these treatment regimens with the demographic population in Malaysia with different genotypes. Subsequently, the project also intends to make Hepatitis C drug available at an affordable price with the involvement of IBV.
Signing on behalf of IBV was Acting President, En Yusri bin Bulat, while CRM were represented by Dr Mohd Akhmal bin Mohd Yusof. Also present to witness the signing ceremony were En Joharizal bin Mahmud, Senior Vice President (Planning); En Mohd Saffuan bin Abd Kudus, Vice President (Sales and Marketing); Pn Emi Sherina binti Md Morad, Vice President (Biopharmaceutical Operations) and En Yau Yit Huan, Chief Accountant of CRM.